Abstract: FR-PO1126
Uptake of Urine Albumin-to-Creatinine Screening Among US Adults at Risk for CKD: Comprehensive Review of Recent Literature
Session Information
- CKD: Screening, Diagnosis, Serum and Urine Biomarkers, and Scoring Indices
November 07, 2025 | Location: Exhibit Hall, Convention Center
Abstract Time: 10:00 AM - 12:00 PM
Category: CKD (Non-Dialysis)
- 2301 CKD (Non-Dialysis): Epidemiology, Risk Factors, and Prevention
Authors
- Chatterjee, Satabdi, Boehringer Ingelheim Pharmaceuticals Inc, Ridgefield, Connecticut, United States
- Bjornson, Alison, Broadstreet HEOR, Vancouver, British Columbia, Canada
- McMullen, Suzanne, Broadstreet HEOR, Vancouver, British Columbia, Canada
- Walker, Sarah, Broadstreet HEOR, Vancouver, British Columbia, Canada
- Donato, Bonnie M.k., Boehringer Ingelheim Pharmaceuticals Inc, Ridgefield, Connecticut, United States
Background
Albuminuria, an integral component of CKD classification and disease progression including cardiovascular (CV) risk, is measured using the urine albumin-creatine ratio (uACR) test. Prior research has reported low uACR screening rates in at-risk patients. This literature review updates the existing evidence base around real-world uACR screening rates among patients at risk for CKD in the US.
Methods
A comprehensive targeted literature review was conducted using iterative key word searching in Google Scholar and Pubmed to identify any evidence generated in the past 5 years (2020-2025) on uACR screening rates, and interventions to improve uptake, in the US. Screening rates by patient populations and screening interventions were summarized.
Results
Ten publications and two grey literature sources were identified (12 studies); all reported on screening rates among patients with type 2 diabetes mellitus (T2DM). Fewer studies reported screening among other at-risk groups (hypertension, 5 studies; heart failure [HF] and coronary artery disease [CAD], 1 study; obesity, 0 studies). Screening rates for uACR ranged from 24.9% (2022-2023; National Patient-Centered Clinical Research Network) to 75.0% (2012-2019; electronic health records [EHR], veterans) in T2DM, and 7.2% (2018; USRDS) to 35.0% (2012-2019; EHR, veterans) in hypertension. In one study, 18.6% of patients with HF and 19.7% of patients with CAD underwent uACR screening (2022-2023; EHR). Another study found that factors associated with poor uACR screening uptake included living in a small rural/isolated area (vs. metropolitan) and having Medicaid/Medicare insurance (vs. commercial). Two studies assessed the role of the Kidney Health Evaluation for Patients with Diabetes (KED) Healthcare Effectiveness Data and Information Set (HEDIS) reporting on the uptake of uACR screening, and reported increased rates of up to 78.5% (2021; Managed Care Organization Atlanta area).
Conclusion
This review continues to highlight the low rates of uACR screening in the US, and the potential of interventions like KED in improving uptake. As elevated albuminuria is one of the earliest indicators of increased CV risk, further intervention is needed to increase uACR screening among at risk patient groups, such as those with T2DM and hypertension.
Funding
- Commercial Support – Boehringer Ingelheim Pharmaceuticals Inc.